Mitsui Chemicals, Inc.

Mitsui Toatsu Chemicals, Incorporated

Mochida Pharmaceutical Co., Ltd.

Miyuki Kawashima

Daisuke Mochizuki

Hitoshi Takahashi

Ryo Tanaka

Hideki Sawai

Takashi Mimitsuka

Tadashi Araki

Mitsufumi Wada

Toshihiro Oikawa

Takashi Morishige

Junko Tokuda

Hitoki Miyake

Yosuke Higashi

Reiko Abe

Yukio Shimazaki

Kiyoshi Sakai

Hisahiro Ishiwari

Masahiko Ishibashi

Mitsufumi Wade

A method for producing D-lactic acid in high yield, and to provide a method for producing D-lactic acid with high selectivity, in which optical purity is high and a by-product organic acid is small. In one aspect, a microorganism, wherein activity of pyruvate formate-lyase (pfl) is inactivated or decreased, and further activity of-derived NADH-dependent D-lactate dehydrogenase (ldhA) is enhanced, is cultured to efficiently produce D-lactic acid. With regard to a method for enhancing ldhA activity, by linking, on a genome, a gene encoding ldhA with a promoter of a gene which controls expression of a protein involved in a glycolytic pathway, a nucleic acid biosynthesis pathway or an amino acid biosynthesis pathway, suitable results are obtained compared to the method for enhancing expression of the gene using an expression vector. A microorganism in which a dld gene is substantially inactivated or decreased is cultured to produce high quality D-lactic acid with reduced concentration of pyruvic acid.

Biocatalyst for production of D-lactic acid

A thrombolytic composition containing tissue type plasminogen activator or a derivative thereof in combination with an anionic polymer or a salt thereof and an amine compound or a salt thereof or in combination with an anionic polymer or a salt thereof, an amine compound and an acid or a salt thereof. The composition is an aqueous solution or a lyophilized preparation which can be stably dissolved on dilution at near neutral pH in both pharmaceutical solutions having high salt concentrations, such as physiological saline, and pharmaceutical solutions having low salt concentrations, such as a 5% glucose solution. Clinically useful products for infusion or injection are prepared to be used at a pH near neutral.

Method of improving solubility of tissue plasminogen activator

Growing community of inventors

Mobara, Japan

Miyuki Kawashima